CapsoVision (CV) Capital Expenditures (2024)

CapsoVision (CV) reported Capital Expenditures of -$154000.0 for Q4 2024, down 198.72% sequentially from $156000.0 in Q3 2024.

CapsoVision (CV) Capital Expenditures (2024) Analysis & Trends

CapsoVision (CV) has 1 years of Capital Expenditures data on file, last reported at -$154000.0 in Q4 2024.

For the quarter ending Q4 2024, Capital Expenditures changed N/A year-over-year to -$154000.0; the trailing twelve-month figure through Dec 2025 stood at $2000.0 (changed N/A YoY), and the FY2024 full-year result was -$1000.0, changed N/A from the prior year.
Capital Expenditures retreated to -$154000.0 in Q4 2024, from $156000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $156000.0 in Q3 2024 to a low of -$154000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	399.00 Mn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	166.00 Mn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	488.00 Mn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	177.00 Mn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	64.90 Mn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	76.60 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	-85.46 Mn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	178.00 Mn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	CapsoVision	162.07 Mn	151.95 Mn	1.95 Mn	-

Download Data